Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group

por Parulekar, W.R., McKenzie, M., Chi, K.N., Klotz, L., Catton, C., Brundage, M., Ding, K., Hiltz, A., Meyer, R., Saad, F.
Publicado 2008

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

por Smith, M. R., Coleman, R. E., Klotz, L., Pittman, K., Milecki, P., Ng, S., Chi, K. N., Balakumaran, A., Wei, R., Wang, H., Braun, A., Fizazi, K.
Publicado 2015

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

por Tolcher, A. W., Chi, K. N., Shore, N. D., Pili, R., Molina, A., Acharya, M., Kheoh, T., Jiao, J. J., Gonzalez, M., Trinh, A., Pankras, C., Tran, N.
Publicado 2012

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

por Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., Azad, A. A., Eigl, B. J., Heng, D. Y. C., Joshua, A. M., de Bono, J. S., Scher, H. I.
Publicado 2016